Table 4.
The relationship between mGPS, NLS and 5-year CSS and OS rates in patients undergoing potentially curative resection of TNM stage II (n = 391) and III (n = 294) colonic cancer
| Stage II (n = 322) | Stage II (n = 322) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mGPS 0 | mGPS 1/2 | mGPS 0–2 | mGPS 0 | mGPS 1/2 | mGPS 0–2 | |||||||
| n | 5-year CSS (%) | n | 5-year CSS (%) | n | n | 5-year OS (%) | n | 5-year OS (%) | n | |||
| NPS 0 | 147 (85%) | 88.4 (0.03) | 78 (52%) | 82.1 (0.04) | 225 | 86.2 (0.02) | 147 (85%) | 66.7 (0.04) | 78 (52%) | 58.7 (0.06) | 225 | 61.3 (0.03) |
| NPS 1/2 | 26 (15%) | 69.2 (0.09) | 71 (48%) | 74.6 (0.05) | 97 | 73.2 (0.05) | 26 (15%) | 57.7 (0.10) | 71 (48%) | 43.7 (0.06) | 97 | 47.4 (0.05) |
| NPS 0–2 | 173 | 85.5 (0.03) | 149 | 78.5 (0.03) | 322 | 82.3 (0.02) | 173 | 65.3 (0.04) | 149 | 47.7 (0.04) | 322 | 57.1 (0.03) |
| Stage III (n = 254) | Stage III (n = 254) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPS 0 | 120 (82%) | 70.0 (0.04) | 50 (46%) | 60.0 (0.07) | 170 | 67.1 (0.04) | 120 (82%) | 54.2 (0.05) | 50 (46%) | 44.0 (0.07) | 170 | 51.2 (0.04) |
| NPS 1/2 | 25 (18%) | 64.0 (0.10) | 59 (54%) | 57.6 (0.07) | 84 | 59.5 (0.05) | 25 (18%) | 48.0 (0.10) | 59 (54%) | 32.2 (0.06) | 84 | 36.9 (0.05) |
| NPS 0–2 | 145 | 69.0 (0.04) | 109 | 58.7 (0.05) | 254 | 64.6 (0.03) | 145 | 53.1 (0.04) | 109 | 37.6 (0.05) | 254 | 46.5 (0.03) |
Values are expressed as % (standard error) survival not calculated if n < 10.
CSS cancer-specific survival, OS overall survival, TNM tumour node metastasis, NLS neutrophil–lymphocyte score, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score